Lantern Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-15.96	-14.26	-12.36	-5.91	-2.43	Upgrade
Depreciation & Amortization	0.17	0.15	0.1	0	0	Upgrade
Share-Based Compensation	1.07	1.19	0.96	1.19	0.12	Upgrade
Other Operating Activities	0.37	0.15	0.71	-0.94	0.18	Upgrade
Operating Cash Flow	-14.35	-12.77	-10.59	-5.65	-2.13	Upgrade
Capital Expenditures	-0.02	-0.03	-0.02	-0.02	-0.01	Upgrade
Change in Investments	-0.91	0.21	-19.52	0	0	Upgrade
Investing Cash Flow	-0.93	0.18	-19.53	-0.02	-0.01	Upgrade
Share Issuance / Repurchase	-0.5	-2.48	68.06	26.25	2.92	Upgrade
Debt Issued / Paid	0	0	0	0.11	0	Upgrade
Other Financing Activities	-	0.3	-4.64	-2.69	-	Upgrade
Financing Cash Flow	-0.5	-2.18	63.42	23.66	2.92	Upgrade
Exchange Rate Effect	-0.03	-0.01	0	0	0	Upgrade
Net Cash Flow	-15.81	-14.78	33.3	18	0.79	Upgrade
Free Cash Flow	-14.37	-12.8	-10.61	-5.67	-2.13	Upgrade
Free Cash Flow Per Share	-1.32	-1.18	-0.97	-1.32	-1.08	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).